
Commentary|Articles|September 2, 2026
BL1332 clears phase 1b: Yehia Hashad, MD, on what's next
Author(s)Yehia Hashad, MD, Lucia Gambuzza
Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients with PRK.
Advertisement
Advertisement
Ocular surface pain remains a persistent clinical challenge, with few therapies designed to interrupt the neurosensory pathways that drive it rather than address the underlying inflammation indirectly. Ophthalmology Times spoke with Yehia Hashad, MD, executive vice president of research and development and chief medical officer at Bausch + Lomb, about the company's investigational TRPV1 antagonist BL1332 and what a recent phase 1b capsaicin challenge study revealed about its mechanism.
Related to this article

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

Kiril Kiprovski, MD, of NYU Langone shares clinical clues and bedside tests for spotting Lambert-Eaton myasthenic syndrome.

BL1332 missed its 24-hour primary end point after PRK, though both doses showed numerically greater pain relief than vehicle.

Esen Akpek, MD, discusses how a systemic Sjögren disease therapy could change dry eye screening, referral and trial end points.

A first-in-class small-molecule Fas inhibitor delivered by intravitreal injection is now under evaluation in more than 324 patients across North America and Europe.

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.
Advertisement
Advertisement


